The FDA cleared PrecivityAD2 on Aug. 20, 2026 to help diagnose Alzheimer's disease in adults age 40 and older who have cognitive symptoms.
For primary care patients, the change means faster, more accurate answers in a familiar clinic, with new guidance on the way. PrecivityAD2 is a blood test that aids diagnosis alongside a standard clinical workup. According to the C2N Diagnostics clearance announcement, it measures Alzheimer's-related proteins from one blood draw and is read together with memory testing, history, and exam findings (C2N Diagnostics clearance announcement).
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from C2N — Use this primary source to verify the official guidance.
- Read the official guidance from Alz — Use this primary source to verify the official guidance.
Table of Contents
- What is different about this clearance?
- How accurate is the test?
- Who can get it, and how?
- What should primary care patients do next?
What is different about this clearance?
The clearance lowers the eligible age to 40 and older for symptomatic adults. According to the Alzheimer's Association statement, PrecivityAD2 is the first FDA-cleared Alzheimer's blood test with that age range, down from the prior 55-and-older floor (Alzheimer's Association statement on the clearance). The test uses high-resolution mass spectrometry. It produces an Amyloid Probability Score from amyloid-beta and p-tau217 ratios in blood.
P-tau217 is a form of tau protein linked to Alzheimer's amyloid buildup. That score sorts patients into Positive, Negative, or intermediate risk for brain amyloid. A doctor combines that result with symptoms, function, medications, and other causes of decline. The blood result alone does not make the diagnosis.
How accurate is the test?
In a 1,142-person study of people with cognitive symptoms, results tracked closely with PET scans and spinal-fluid tests for amyloid. According to the Practical Neurology report, a Positive result was correct 97.6% of the time and a Negative result was correct 93.1% of the time (Practical Neurology report on the validation data). The primary-care impact was large in a second study. It enrolled 1,310 patients and 165 physicians in real-world practice.
According to the AAIC 2026 release, primary-care accuracy rose from 65% to about 93% after doctors saw the blood-test result, matching specialists at about 90% (Alzheimer's Association AAIC 2026 release). That gain matters because most memory concerns start in primary care. A more accurate first evaluation can reduce wrong diagnoses. It can also speed referral for treatment, trials, or other causes such as sleep apnea, depression, or medication effects.
Who can get it, and how?
The test is only for people already being evaluated for cognitive decline. It is not screening for healthy adults. It also is not a standalone diagnosis without clinical assessment.
Patients can ask their clinic about these checks: The FDA-cleared kit is expected later in 2026. C2N's lab-processed version remains available in the meantime. Patients will still need a clinician visit, blood draw, and follow-up to review results.
- ongoing memory, thinking, or behavior changes noticed by the patient or family
- age 40 or older with symptoms that prompt cognitive evaluation
- exam and history to rule out other causes
- order placed by a clinician experienced in cognitive evaluation
What should primary care patients do next?
Bring specific examples to the visit. Note when forgetting started, which tasks changed, and what a partner or coworker observed. List sleep, mood, head injury, alcohol use, and all drugs and supplements. Ask what a Positive, Negative, or uncertain result would change.
A Positive result may lead to confirmatory testing, specialist referral, care planning, or discussion of Alzheimer's drugs and trials. A Negative result points the doctor toward other causes and next tests. For next steps, the Alzheimer's Association said it published blood-biomarker guidelines and is preparing a concise primary-care decision tool. Ask whether your clinic follows that guidance for test selection, counseling, and follow-up.
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Accuracy, Limits, and Evidence Gaps for Primary Care Patients
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Accuracy, Limits, and Evidence Gaps for Primary Care Patients
- Strengths-Based Dementia Care in the 2026 NIA Report: What Changed and What Comes Next for Spouses and Partners
